Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results PR_BPTH_2012_3RD_QTR_Op_Results
Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia Press_release_re_4th_Cohort_and_Earnings_Release
Bio-Path Holdings to Present at the 11th Annual Bio Investor Forum Conference in San Francisco on Wednesday Oct 10, 2012 at 11:30 am Pacific Time (2:30 pm Eastern Time) PR_Bio_Investor_Forum_10_12
Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference PR_2012_09_04_Rodman__Renshaw
Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias PR_start_of_cohort4_7_25_12
Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia PR_Third_cohort_5_29_12
Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results – Quarter Highlighted by Progress with Lead Product Candidate, Liposomal Grb-2 PR_1Q12_5_17_12
